I'll start, and then Stephen Bent, who's in charge of procurement, can supplement.
I think it's very important to get the clinical trials looked at in terms of the Moderna bivalent vaccines. We're looking forward to the data—we hope over the next month—on the bivalent ancestral strain, plus an omicron strain, but the proof of concept with a beta variant strain is promising. I know that, with our contractual arrangements, we have made provisions to purchase new formulations.
I don't know if Stephen has anything else to add.